Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALFA 2101: CPX-351 vs intensive chemotherapy in de novo intermediate/adverse-risk AML
2022-500295-60-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by Centre Hospitalier Universitaire de Nice. Primary endpoint: Primary: Proportion of patients achieving CR/CRi with flow MRD < 10^-3 after first induction. Planned start Jul 2022; status: authorised.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2022-500295-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500295-60-00.